Is Weakness In Getein Biotech, Inc (SHSE:603387) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Is Weakness In Getein Biotech, Inc (SHSE:603387) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
With its stock down 20% over the past three months, it is easy to disregard Getein Biotech (SHSE:603387). But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to Getein Biotech's ROE today.
由于其股票在过去三个月中下跌了20%,因此很容易忽视Getein Biotech(上海证券交易所代码:603387)。但是,如果你密切关注,你可能会发现,鉴于市场通常会奖励财务状况良好的公司,其强劲的财务状况可能意味着该股的长期价值可能会增加。特别是,我们今天将关注Getein Biotech的投资回报率。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率或投资回报率是用于评估公司管理层利用公司资本效率的关键指标。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。
How Is ROE Calculated?
ROE 是如何计算的?
The formula for ROE is:
ROE 的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Getein Biotech is:
因此,根据上述公式,Getein Biotech的投资回报率为:
9.6% = CN¥257m ÷ CN¥2.7b (Based on the trailing twelve months to September 2023).
9.6% = 2.57亿元人民币 ÷ 27亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' is the amount earned after tax over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.10.
“回报” 是过去十二个月的税后收入。因此,这意味着其股东每投资1元人民币,公司就会产生0.10元人民币的利润。
What Is The Relationship Between ROE And Earnings Growth?
投资回报率与收益增长之间有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我们已经确定,投资回报率是衡量公司未来收益的有效利润创造指标。我们现在需要评估公司为未来增长再投资或 “保留” 了多少利润,这样我们就可以了解公司的增长潜力。假设其他一切都保持不变,那么与不一定具有这些特征的公司相比,投资回报率和利润保留率越高,公司的增长率就越高。
A Side By Side comparison of Getein Biotech's Earnings Growth And 9.6% ROE
Getein Biotech的收益增长和9.6%的投资回报率的并排比较
When you first look at it, Getein Biotech's ROE doesn't look that attractive. Although a closer study shows that the company's ROE is higher than the industry average of 5.8% which we definitely can't overlook. Consequently, this likely laid the ground for the decent growth of 12% seen over the past five years by Getein Biotech. Bear in mind, the company does have a moderately low ROE. It is just that the industry ROE is lower. So there might well be other reasons for the earnings to grow. E.g the company has a low payout ratio or could belong to a high growth industry.
当你第一次看的时候,Getein Biotech的投资回报率看起来并不那么吸引人。尽管一项更仔细的研究表明,该公司的投资回报率高于行业平均水平的5.8%,但我们绝对不能忽视。因此,这可能为Getein Biotech在过去五年中实现12%的可观增长奠定了基础。请记住,该公司的投资回报率确实适度低。只是行业的投资回报率较低。因此,收益增长很可能还有其他原因。例如,该公司的派息率较低,或者可能属于高增长行业。
We then compared Getein Biotech's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 5.2% in the same 5-year period.
然后,我们将Getein Biotech的净收入增长与该行业进行了比较,我们很高兴地看到,与该行业相比,该公司的增长数字更高,该行业在同期的5年增长率为5.2%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240417/0-87212d92c2e6746c0bd24fa8d870ea84-0-f2ac2d81873a73a388381ec5336eb056.png/big)
Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Getein Biotech is trading on a high P/E or a low P/E, relative to its industry.
收益增长是对股票进行估值时要考虑的重要指标。无论如何,投资者应设法确定预期的收益增长或下降是否已计入其中。通过这样做,他们将知道股票是走向清澈的蓝色海水还是沼泽水域在等着呢。衡量预期收益增长的一个很好的指标是市盈率,它根据收益前景决定了市场愿意为股票支付的价格。因此,您可能需要检查与其行业相比,Getein Biotech的交易市盈率是高还是低。
Is Getein Biotech Efficiently Re-investing Its Profits?
Getein Biotech是否有效地将其利润再投资?
Getein Biotech has a three-year median payout ratio of 31%, which implies that it retains the remaining 69% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently.
Getein Biotech的三年派息率中位数为31%,这意味着它保留了剩余的69%的利润。这表明其股息覆盖范围良好,鉴于该公司的可观增长,管理层似乎正在有效地对其收益进行再投资。
Additionally, Getein Biotech has paid dividends over a period of six years which means that the company is pretty serious about sharing its profits with shareholders.
此外,Getein Biotech已在六年内派发了股息,这意味着该公司非常认真地与股东分享利润。
Summary
摘要
In total, we are pretty happy with Getein Biotech's performance. Specifically, we like that it has been reinvesting a high portion of its profits at a moderate rate of return, resulting in earnings expansion. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Not to forget, share price outcomes are also dependent on the potential risks a company may face. So it is important for investors to be aware of the risks involved in the business. You can see the 3 risks we have identified for Getein Biotech by visiting our risks dashboard for free on our platform here.
总的来说,我们对Getein Biotech的表现非常满意。具体而言,我们喜欢它一直在以适度的回报率再投资其很大一部分利润,从而实现了收益的扩张。考虑到每股收益如何影响长期股价,如果该公司继续以现有方式增长收益,这可能会对其股价产生积极影响。别忘了,股价结果还取决于公司可能面临的潜在风险。因此,投资者必须意识到业务所涉及的风险。您可以通过访问我们的 Getein Biotech 查看我们已确定的 3 种风险 风险仪表板 在我们的平台上免费使用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。